Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) (CHIMERA)
Radiotherapy is thought to trigger an immune response, and the particular type of immune response may depend on the biology of individual tumours. By studying changes in the immune response and tumour biology during and after radiotherapy, we will gain a better understanding of how different types of radiotherapy, and different tumour types, affect the immune response. This is important for optimising personalised radiotherapy treatment, including in combination with other immunotherapy agents. There is minimal published data reporting feasibility of the above approach, or to guide power calculations. This means pilot work is needed to establish both feasibility and proof-of principle.
The CHIMERA protocol is a non-interventional single site study involving sample collection (blood and tumour samples) from patients before, during and after radiotherapy. A maximum of four tumour research biopsies are further optional research samples. The primary and secondary objectives of the CHIMERA protocol are to establish feasibility of longitudinal characterisation of firstly the immune response, and secondly tumour biology before, during and after radiotherapy.
Any patient receiving radiotherapy at The Royal Marsden NHS Trust is eligible for CHIMERA provided they are able to provide informed consent, attend follow up appointments and do not have an immunosuppressive infection.
If feasibility criteria are met for profiling of the immune response and tumour, CHIMERA will provide both preliminary data and proof-of-principle for larger studies in single tumour sites. CHIMERA is sponsored by the Institute of Cancer Research, LONDON. Funding is also provided by the Institute of Cancer Research.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Anna Dr Wilkins, FRCR, MRCP, MB
- 电话号码:4020 0208 642 6011
- 邮箱:Anna.Wilkins@icr.ac.uk
研究联系人备份
- 姓名:Abigail Ms Crowhurst, Masters
- 电话号码:4020 0208 642 6011
- 邮箱:Abigail.Crowhurst@rmh.nhs.uk
学习地点
-
-
-
London、英国、SW3 6JJ
- 招聘中
- Royal Marsden NHS Foundation Trust
-
接触:
- Anna Wilkins, FRCR, MRCP, MB
- 电话号码:4020 0208 642 6011
- 邮箱:Anna.Wilkins@icr.ac.uk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients receiving any type of radiotherapy are eligible for CHIMERA with lung, head and neck, bladder, cervical or rectal cancer
描述
Inclusion Criteria:
- Patients receiving any type of radiotherapy are eligible for CHIMERA provided they are at least 18 years of age and can attend routine follow up appointments
Exclusion Criteria:
- As immunodeficiency due to HIV/AIDS or other infective or autoimmune immunological conditions may impact feasibility and results of immune profiling, immunosuppressed patients due to infection such as HIV, Hepatitis B/C are excluded.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Lung cancer 1
5 patients with peripheral lung tumours and 5 patients with central lung tumours receiving radical radiotherapy without chemotherapy will be recruited. |
Tissue and blood sample collection |
|
Lung cancer 2
12 patients. To establish the feasibility of ctDNA profiling before, during and after radiotherapy for non-small cell lung cancer (NSCLC). |
Tissue and blood sample collection |
|
Head and Neck cancer
This pilot includes 12 patients (6 HPV+ and 6 HPV-) head and neck cancer patients |
Tissue and blood sample collection |
|
Cervical cancer
12 patients to establish the feasibility of tumour TCR-Seq profiling before, during and after radiotherapy for cervix cancer. This includes patients receiving either radiotherapy or chemoradiotherapy |
Tissue and blood sample collection |
|
Bladder cancer 1
12 patients to establish the feasibility of collecting urine-derived lymphocytes suitable for flow cytometry before, during and after chemoradiotherapy. |
Tissue and blood sample collection |
|
Bladder cancer 2
24 patients To establish the feasibility of tumour TCR-Seq profiling before, during and after chemoradiotherapy for bladder cancer, in comparison to a cystectomy sample. |
Tissue and blood sample collection |
|
Rectal cancer 1
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during chemoradiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
|
Rectal cancer 2
12 patients To determine the feasibility of detecting changes in gene expression using multiple tissue samples during radiotherapy treatment for rectal cancer |
Tissue and blood sample collection |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The feasibility of measuring the change in immune cell repertoire before, during and after radiotherapy
大体时间:defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
establishment of proof-of-principle that immune changes occur during and after radiotherapy. Measurement tool is multiparametric flow cytometry immune panel. |
defined as successful profiling of the immune cell repertoire in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy
大体时间:Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
The feasibility of evaluation of ctDNA dynamics before, during and after radiotherapy. Measurement tool is targeted DNA sequencing with reference to baseline tumour. |
Feasibility is defined as successfully measurement of ctDNA dynamics in 80% of patients. Time frame is across blood samples which are taken from baseline to 12 months after radiation and at progression if this occurs.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 4893
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
No plan
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.